comparemela.com

Latest Breaking News On - Cullinan oncology - Page 1 : comparemela.com

EGFR Inhibitors Market to Grow at a decent CAGR during the Study Period (2020–2034) by

EGFR Inhibitors Market to Grow at a decent CAGR during the Study Period (2020–2034) by
wn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wn.com Daily Mail and Mail on Sunday newspapers.

HC Wainwright Trims Cullinan Oncology (NASDAQ:CGEM) Target Price to $28 00

Cullinan Oncology (NASDAQ:CGEM – Free Report) had its price target decreased by HC Wainwright from $29.00 to $28.00 in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. Several other equities analysts have also issued reports on CGEM. Jonestrading lifted their price objective on shares of […]

Cullinan Oncology, Inc (NASDAQ:CGEM) Given Average Rating of Buy by Analysts

Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) have been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued a report […]

Brokerages Set Cullinan Oncology, Inc (NASDAQ:CGEM) Price Target at $31 00

Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year […]

CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024

CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.